The
Rna
Dna
Difference
Company
Genclis SA
Develops Precise
Predictive Medicine
3 Patents
Rna
Dna
Differences

« Genomic
     Clinical
          Synergy »

Our objectives:
– To answer unresolved medical questions by innovative solutions that are complete, precise, appropriate, and simple
– To facilitate the decision-making process of healthcare professionals
– To allow the personalization of treatments, while increasing their efficiency and reducing costs
photo_accueil

Our Mission

To develop tools required for precise predictive medicine.

GENCLIS is specialized in the analysis of low-intensity signals of RNA-DNA differences (RDDs). GENCLIS is the first and, at this stage, the only company to possess a patent on this discovery. Measuring the levels of RDDs and their components enables the prediction of cancer severity.

« The difference between a low-intensity signal that precedes any major transformation and noise is that the second is random, while the first is not. »

Bernard Bihain
 
entree_accueil_equipe
entree_accueil_produit